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Background: The main cause of treatment failure and death in laryngeal squamous cell carcinoma is metastasis to
the regional lymph nodes. The current clinical staging criteria fail to differentiate patients with occult metastasis
from patients without metastasis. Identifying molecular markers of the disease might improve our understanding of
the molecular mechanisms underlying the pathogenesis and development of laryngeal carcinoma and may help
improve clinical staging and treatment.
Methods: Sixty-four previously untreated patients who underwent surgical excision of laryngeal squamous cell
carcinoma with neck dissection were included in this study. The expression of B cell-specific Moloney
murine leukemia virus integration site 1 (BMI-1) was examined immunohistochemically on formalin-fixed
paraffin-embedded primary tissue specimens.
Results: Nuclear expression of BMI-1 (nBMI-1) was detected in 32 of the 64 tumors (50%), cytoplasmic expression of
BMI-1 (cBMI-1) was detected in 22 (34.4%), and 10 tumors (15.6%) showed no BMI-1 immunoreactivity. High nBMI-1
expression levels (≥10) were detected in 28 of the 32 (87.5%) nBMI-1-positive patients. Multivariate analysis
including age at diagnosis, grade, tumor location, TNM status, and nBMI-1 expression showed that a high nBMI-1
expression level was an independent prognostic factor for lymph node metastasis.
Conclusion: The expression of BMI-1 in patients with laryngeal carcinoma seems to correlate with lymph node
metastasis.
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Laryngeal squamous cell carcinoma is the most common
type of head and neck cancer, and its incidence rate in
Italy is approximately 5,000 new cases per year [1]. Most
patients affected by laryngeal cancer are in the locore-
gionally advanced stage of disease at the time of diagno-
sis. The main cause of treatment failure and death is
metastasis to the regional lymph nodes and distant me-
tastasis [2]. The current clinical staging criteria fail to
differentiate patients with occult metastasis from
patients without metastasis. Many investigators are cur-
rently working to identify molecular markers of the dis-
ease to improve our understanding of the molecular* Correspondence: eualle@unicz.it
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reproduction in any medium, provided the ormechanisms underlying the pathogenesis and develop-
ment of laryngeal carcinoma and to improve its clinical
staging.
Recently, B cell-specific Moloney murine leukemia
virus integration site 1 (BMI-1) seems to be a new puta-
tive marker for head and neck solid tumors.
BMI-1 is an essential constituent of the polycomb re-
pressive complex-1, a key epigenetic regulator. BMI-1
controls the cell cycle and self-renewal of tissue stem
cells by regulating chromatin and histone structures.
BMI-1 was identified initially as an oncogene that coop-
erates with c-Myc in the generation of mouse pre-B cell
lymphomas, and it has been implicated in the mainten-
ance of self-renewal of neural, hematopoietic, and intes-
tinal stem cells [3]. BMI-1 protein, together with c-Myc
protein, regulates the INK4a/ARF locus, which encodes
two unrelated tumor suppressors, p16INK4a and p19ARF,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(pRb and p53, respectively). BMI-1 is highly expressed in
breast cancer [4], colorectal cancer [5], prostate cancer
[6], metastatic melanoma [7] and non-small cell lung
cancer [8]. At this time very few studies have been made
on BMI-1 expression in head and neck tumors. Because
of discordant results with regard to nasopharyngeal car-
cinoma [9], oral squamous cell carcinoma [10] and la-
ryngeal carcinoma [11] no definitive conclusions can be
made.
The objective of this study was to evaluate immuno-
histochemically the expression of BMI-1 in laryngeal
carcinomas and to determine its clinical significance.Methods
Patients
Previously untreated patients who underwent surgical
excision of laryngeal squamous cell carcinoma with neck
dissection in the Department of Otolaryngology-Head
and Neck Surgery ENT ‘Magna Graecia’ University of
Catanzaro between January 2004 and December 2009
were considered for this study. From the original 72
patients, eight were subsequently excluded because of
the poor quality of the histopathological sample available
for review or loss to follow-up. Sixty-four patients were
included in this study.
Fifty-eight of the 64 patients were men and six were
women; their median age was 67 ± 13.0 years (range 43
to 86 years). Twenty-three (35.9%) of the 64 patients had
a glottic localization and 41 (64.1%) had a supraglottic
localization. The histological grade was G1 in 8 cases,
G2 in 36, and G3 in 18. All were stage III–IV. According
to the TNM classification, the stages of the primary
tumors were T2 in 24 patients, T3 in 31, and T4 in 9.
Forty-seven patients underwent a total laryngectomy, 12
had a supraglottic laryngectomy, and 5 had a supracri-
coid laryngectomy. The clinical classification of the re-
gional lymph nodes was N0 in 11, N1 in 22, N2a in 13,
N2b in 14, and N2c in 4 patients. Twenty-eight patients
had unilateral neck dissection and 36 had bilateral neck
dissection. A total of 100 hemineck dissections were per-
formed; 42 were selective (Levels II to IV) and 58 were
modified (type II to III). Pathological examination
showed that 33 of the 64 patients (51.5%) had lymph
node metastasis. All of these patients underwent post-
operative radiation.
All patients included in this study were followed up
every three months; the median clinical follow-up was
36 ± 21.5 months.
The protocol was approved by the Institutional Re-
view Board of ‘Magna Graecia’ University of Catanzaro.
All patients were informed before giving informed
consent.Immunohistochemistry
The specimens derived from primary tumors were fixed
in 10% buffered formalin, processed routinely, and em-
bedded in paraffin. Four-micrometer-thick sections were
stained with H & E for histological evaluation of the spe-
cimens. Additional sections were prepared for immuno-
histochemical analysis. The immunohistochemical assay
was performed on 4 μm-thick sections cut from the
blocks and float-mounted on Super Frost/Plus slides.
Slides were deparaffinized and rehydrated through xy-
lene and graded ethanol to water. Antigen retrieval was
performed using a heat-induced method in which the
specimens were placed in a citric acid solution (Target
Retrieval Solution, pH 6.1; Dako Cytomation, Glostrup,
Denmark) for 30 min at 94°C in a vegetable steamer and
then brought to room temperature within 20 min. All
slides were quenched for 5 min in 0.03% hydrogen per-
oxide (EnVision + System-HRP (DAB); Dako Cytoma-
tion) to block endogenous peroxidase. The primary
antibody, mouse anti-human BMI-1 antibody (R&D Sys-
tems, Minneapolis, MN, USA) diluted 1:100), was ap-
plied for 60 min in a moist chamber. After washing in
Tris-buffered saline (TBS) at pH 7.6, the MACH 4 Uni-
versal HRP-Polymer kit (Biocare Medical, Concord, CA,
USA) was applied for 60 min as the detection system.
The sections were washed again in TBS. Staining was
completed with a 10 min incubation with 3,30-diamino-
benzidine substrate chromogen (Dako Cytomation).
Slides were counterstained in hematoxylin, dehydrated
through graded ethanol solutions, and mounted using an
aqueous medium (Faramount, Dako Cytomation).
The staining intensity of BMI-1 was evaluated as
negative (0), weak (1), moderate (2), or strong (3), as
described previously [11]. The percentage of positive
cells was used to classify scores for specimens as fol-
lows: negative (score 0); 1% to 10% stained cells (score
1); 11% to 30% stained cells (score 2); 31% to 50%
stained cells (score 3); 51% to 80% stained cells (score
4); and >80% stained cells (score 5). The staining in-
tensity was multiplied by the percentage of positive
cells to obtain an intensity reactivity score (IRS).
Patients were classified into three groups based on the
IRS: IRS = 0 (no expression), IRS <10 (low expres-
sion), and IRS ≥10 (high expression) [12]. Nuclear or
cytoplasmic BMI-1 expression was also evaluated.Statistical analysis
Statistical analysis was performed with MedCalc software
(Mariakerke, Belgium) using the chi-squared test and
Fisher’s exact test. All reported P values are two-tailed
and P <0.05 was considered significant. Overall survival
(OS) and disease-specific survival (DSS) were calculated
according to the Kaplan–Meier method. Multivariate
Table 1 Correlation between nBMI-1 expression and
clinicopathological data
Clinical data N BMI-1 nuclear expression negative or
low high
Localization
Glottic 23 14 9
Supraglottic 41 22 19
P = 0.61
Histological grade
G1 8 6 2
G2 36 20 16
G3 18 10 8
*P = 0.38
T classification
T2 24 16 8
T3 31 19 12
T4 9 1 8
*P = 0.01
N clinical status
N0 11 7 4
N+ 53 29 24
P= 0.74
N pathological status
N0 31 31 0
N+ 33 5 28
P = 0.0001
*Chi-square test. nBMI-1, nuclear BMI-1.
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tic factors using multiple regression analysis.
Results
Nuclear expression of BMI (nBMI-1) in tumor cells was
detected in 32 of the 64 tumors (50%) (Figure 1), cyto-
plasmic expression of BMI-1 (cBMI-1) was detected in
22 (34.3%), and 10 tumors (15.6%) showed no BMI-1
immunoreactivity. High levels (IRS ≥10) of nBMI-1
expression were detected in 28 of the 32 (87.5%) nBMI-
1-positive patients. The patients’ clinical data were strati-
fied according to nBMI-1 expression into a negative or
low (0 to 10) group and a high nuclear expression (≥10)
group (Table 1). High expression of nBMI-1 was
detected in 39.1% of the glottic tumors and in 46.2% of
the supraglottic tumors, although this difference was not
significant (P = 0.61). There was also no significant cor-
relation between nBMI-1 expression and histological
grade (P = 0.38). High expression of nBMI-1 was
detected in 33.3% of the T2 tumors, in 38.7% of the T3
tumors, and in 88.8% of the T4 tumors (P = 0.01). Four
of the 11 (36.3%) patients with clinically negative nodes
showed high nBMI-1 expression and 29/53 (54.7%) of
those with clinically positive nodes showed high expres-
sion of nBMI-1 (P = 0.74). None of the 31 patients with
negative pathological nodes showed high nBMI-1 ex-
pression in their primary tumors. By contrast, 84.8%
(28/33) of those with positive pathological nodes showed
high expression of nBMI-1 (P <0.0001).
The multivariate analysis included age at diagnosis,
grade, tumor location, T and N classification, TNM sta-
tus, and nBMI-1 expression. A high expression of nBMI-
1 was an independent prognostic factor for lymph node
metastasis (P = 0.0002).
Cytoplasmic staining for BMI-1 was detected in 22 of
the 64 primary tumors; 9 of these (40.9%) showed a highFigure 1 The expression of BMI-1 protein in laryngeal
carcinoma. High nuclear BMI-1 expression (SP 200×).expression level (≥10) (Figure 2). None of the 33 primary
tumors associated with metastatic lymph nodes showed
cytoplasmic immunoreactivity for BMI-1. However, six
of the nine patients with high levels of cBMI-1 died of
distant metastasis.
High cBMI-1 expression correlated significantly with
distant metastasis (P <0.05), and negative or low
cBMI-1 expression correlated with negative lymph
nodes (P <0.05) (data not shown).
The three-year OS and DSS of the 64 patients were
57.8% and 68.7%, respectively. The three-year specific
survival was 77.7% (28/36) in the cohort of patients
expressing no or low three-year specific survival was
77.7% (28/36) in the cohort of patients expressing no or
low levels of nBMI-1 (0 to 10) and 57.1% (16/28) in the
group of patients with high nBMI-1 expression (P =
0.058) (Figure 3). Multivariate analysis showed no sig-
nificant correlation between high nBM-I expression and
poor survival (P = 0.48, significance level P = 0.24).
In the patients with no or low expression of nBMI-1,
the specific cause of death was distant metastasis in all
cases. In the patients with high expression of nBMI-1,
Figure 2 The expression of BMI-1 protein in laryngeal
carcinoma. High cytoplasmatic BMI-1 expression (SP 200×).
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mary tumor in two patients, recurrence of lymph node
metastasis in six patients, and distant metastasis in four
patients.Discussion
Lymph node metastasis represents the most adverse
clinical prognostic factor and decreases OS by about
50% [13].
Clinical determination of lymph node metastasis made
by palpation, computed tomography (CT), and magneticFigure 3 Disease-specific survival. The three-year specific survival
in the cohort of patients expressing no or a low level of nBMI-1
compared with patients with high expression of nBMI-1 (P = 0.058).
nBMI-1, nuclear BMI-1.resonance imaging (MRI) has a sensitivity of 38% to 78%
for occult metastatic lymph nodes [14,15] and a 7% to
37% probability of metastatic lymph nodes in patients
classified with N0 disease [16]. To improve the choice of
the modality of treatment, immunohistochemical and
molecular prognostic markers should be useful for iden-
tifying patients with occult metastasis at diagnosis [17].
In this study, we report a correlation between the clin-
ical data at diagnosis and BMI-1 expression in primary
tumors from patients affected by laryngeal carcinoma.
The most relevant finding from the study was the sig-
nificantly high nBMI-1 expression detected in primary
tumors from patients with metastatic lymph nodes.
A previous study by Chen et al. [11] on 20 laryngeal
carcinomas reported a higher expression of BMI-1 cor-
related with advanced stage of disease and well differen-
tiated histological grade. A correlation between T and
N classification and prognostic significance was not
reported in this study. However, the higher expression
of BMI-1 in the advanced stage of disease can be due,
in agreement with our previous results [18], to the T
and N status of the patients classified as advanced clin-
ical stage.
In our study the expression of nBMI-1 correlated sig-
nificantly with T classification and pathological N status.
The multivariate analysis showed that nBMI-1 expression
was the sole independent prognostic factor for lymph
node metastasis, although it failed as an independent
prognostic factor of poor DSS. This suggests that the ex-
pression of BMI-1 is a reliable marker of the presence of
lymph node metastases at diagnosis. We detected cBMI-
1 expression in 34.3% of the primary laryngeal tumors.
cBMI-1 expression did not correlate with lymph node
metastasis, but high cBMI-1 expression correlated sig-
nificantly with distant metastasis (P = 0.001).
The clinical implications of BMI-1 expression in head
and neck tumors are unclear because there are few clinical
studies. Hayry et al. [19] reported that negative nBMI-1
expression seems to correlate with poor recurrence-free
survival at two years in early tongue squamous cell carcin-
omas (T1–T2N0). They found nBMI-1 positivity in 82%
of cases, but they did not report any cytoplasmic expres-
sion. They also reported that nBMI-1 expression was a
prognostic marker in patients undergoing elective neck
dissection.
Huber et al. [12] studied tumors of the oropharynx
and oral cavity and reported that 21.4% of tumors were
positive for nBMI-1 and 27% for cBMI-1. In their study,
cytoplasmic positivity was inversely related to OS and
DSS, but this correlation was significant only for cancers
of the oropharynx. The DSS was significantly better in
patients with oropharyngeal cancer with low levels of
nBMI-1, although the results of the multivariate analysis
were not significant.
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with the findings of Huber et al. and Hayry et al. [19]
showing that nBMI-1 does not correlate with OS or with
specific survival. Furthermore, some common elements
emerge. These earlier studies and our study suggest that
nBMI-1 is related to the capacity for lymph node metas-
tasis, whereas cBMI-1 appears to correlate with the cap-
acity for distant metastases.
In the study by Hayry et al. [19], tongue tumors were
all early stage and expressed only nuclear staining,
which correlated with the N state but not with the
prognosis. By contrast, Huber et al. [12] found greater
cytoplasmic expression than nuclear expression, and a
correlation between cytoplasmic expression and poor
DSS. This suggests that the nuclear and cytoplasmic ex-
pression of BMI-1 have different roles in the progres-
sion of tumors of the head and neck. This may explain
why nuclear and cytoplasmic BMI-1 expression levels
were not significant independent predictors of OS or
DSS when considered separately in the multivariate
analysis. Nuclear expression appears to play a signifi-
cant role in the lymph node-metastasizing capacity,
whereas cytoplasmic expression appears to play a role
in the ability to metastasize to distant sites.
Recent evidence shows that head and neck tumor
growth and progression depend on a subset of cells
defined as ‘cancer stem cells’ [20,21] that possess the
ability for self-renewal within a tumor expressing differ-
ent phenotypes, which are responsible for resistance to
chemo-radiotherapy and the capacity to metastasize lo-
cally or to distant sites.
In laryngeal carcinomas in particular, it has been
revealed that cancer stem cells expressing the isoform
v3 of CD44 surface antigen seem to have the ability
for lymph node metastasis while those expressing the
isoform v6 of CD44 seem to have ability for distant
metastasis [22].
BMI-1 is considered to be a stem cell-related gene that
is implicated in the tumorigenesis of head and neck
tumors [21]; its nuclear or cytoplasmatic expression
could be related to the cancer stem cell phenotype in
which it is expressed. However, it is not yet known
whether the nuclear and cytoplasmic expression of BMI-
1 varies between different subsets of stem cells. The cor-
relation found in this study between nBMI-1 expression
and pN staging suggests that BMI-1 is a potential candi-
date marker in treatment planning for the neck in a sub-
set of patients with clinically N0 laryngeal cancer.
Further studies are needed to confirm our hypothesis.
Conclusions
The expression of BMI-1 in patients with laryngeal car-
cinoma seems to be a potential marker of tumor aggres-
siveness. A high BMI-1 expression may detect lymphnode metastasis at diagnosis and can be useful in a sub-
set of patients to decide on neck treatment.
However, further and larger studies are needed to con-
firm our results.
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